HC Wainwright reiterated their buy rating on shares of Onconova Therapeutics (NASDAQ:ONTX) in a report published on Thursday. HC Wainwright currently has a $6.00 price target on the biopharmaceutical company’s stock.

ONTX has been the topic of several other research reports. Maxim Group restated a buy rating and issued a $6.00 price target on shares of Onconova Therapeutics in a research note on Thursday, November 2nd. Zacks Investment Research upgraded shares of Onconova Therapeutics from a sell rating to a hold rating in a research note on Wednesday, January 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The stock has an average rating of Hold and a consensus price target of $7.33.

Shares of Onconova Therapeutics (NASDAQ:ONTX) opened at $1.77 on Thursday. Onconova Therapeutics has a 12 month low of $1.21 and a 12 month high of $3.88. The company has a market cap of $19.06, a P/E ratio of -0.58 and a beta of 0.10.

Onconova Therapeutics (NASDAQ:ONTX) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02. Onconova Therapeutics had a negative net margin of 2,855.94% and a negative return on equity of 558.97%. The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.29 million. research analysts forecast that Onconova Therapeutics will post -2.82 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. 683 Capital Management LLC increased its stake in shares of Onconova Therapeutics by 21.0% during the third quarter. 683 Capital Management LLC now owns 375,000 shares of the biopharmaceutical company’s stock valued at $641,000 after acquiring an additional 65,140 shares during the period. Tyndall Capital Partners L P increased its stake in shares of Onconova Therapeutics by 91.4% during the second quarter. Tyndall Capital Partners L P now owns 997,022 shares of the biopharmaceutical company’s stock valued at $2,154,000 after acquiring an additional 476,190 shares during the period. Sabby Management LLC increased its stake in shares of Onconova Therapeutics by 104.0% during the second quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock valued at $1,693,000 after acquiring an additional 399,640 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Onconova Therapeutics by 58.4% during the second quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock valued at $190,000 after acquiring an additional 32,418 shares during the period. Institutional investors and hedge funds own 25.44% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Onconova Therapeutics (ONTX) Receives “Buy” Rating from HC Wainwright” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/22/onconova-therapeutics-ontx-receives-buy-rating-from-hc-wainwright.html.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.